CAJ | 학술논문

肾癌是肾脏最常见的恶性疾病，对放疗及化疗多不敏感，手术根治是以往肾癌的主要治疗手段。自索拉非尼作为第一个用于转移性肾癌靶向药物问世以来，越来越多的靶向药物投入到了临床研究与应用中，并取得了巨大的成功。本文结合2013版欧洲《肾癌指南》，对肾细胞癌靶向治疗药物的临床疗效、不良反应、药物间联合及序贯使用等情况进行了介绍。
신암시신장최상견적악성질병，대방료급화료다불민감，수술근치시이왕신암적주요치료수단。자색랍비니작위제일개용우전이성신암파향약물문세이래，월래월다적파향약물투입도료림상연구여응용중，병취득료거대적성공。본문결합2013판구주《신암지남》，대신세포암파향치료약물적림상료효、불량반응、약물간연합급서관사용등정황진행료개소。
Renal cell carcinoma is the most common malignant disease which is insensitive to radiotherapy, chemotherapy and radical surgery that was the main treatment for kidney cancer in the past. Since sorafenib was as the ifrst one of the advent of targeted drugs for metastatic renal cell carcinoma, more and more targeted drugs have been researched and applied in clinic and achieved great success. This article introduces the clinical efifcacy, adverse reactions, drug-drug combination and sequential use of targeted therapy for the renal cell carcinoma.